title: Atorvastatin Protects Myocardium Against Ischemia-Reperfusion Injury Through Inhibiting miR-199a-5p.
abstract: OBJECTIVE
  This study aimed to evaluate the protective effects of atorvastatin against myocardial ischemia/reperfusion (I/R) injury in cardiomyocytes and its possible underlying mechanism.
  
  
  METHODS
  Direct cytotoxic effect of OGD/R on cardiomyocytes with and without atorvastatin pretreatment was evaluated. Effects of atorvastatin on expression of GSK-3β and miR-199a-5p were determined using RT-PCR and Western blot. In addition, GSK-3β expression with miR-199a-5p upregulation and downregulation was detected using RT-PCR, Western blot, and immunohistochemistry.
  
  
  RESULTS
  Pretreatment with atorvastatin significantly improved the recovery of cells viability from OGD/R (p<0.05). In addition, the atorvastatin pretreatment significantly increased GSK-3β expression both in mRNA level and protein level and decreased miR-199a-5p expression in mRNA level (p<0.05). Upregulation and downregulation of miR-199a-5p respectively decreased and increased GSK-3β expression both in mRNA level and protein level.
  
  
  CONCLUSIONS
  These results suggested that atorvastatin provides the cardioprotective effects against I/R injury via increasing GSK-3β through inhibition of miR-199a-5p.
authors.affiliation: Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
authors.forename: YaBei
authors.initials: Y
authors.lastname: Zuo
authors.forename: YuZhao
authors.initials: Y
authors.lastname: Wang
authors.forename: HaiJuan
authors.initials: H
authors.lastname: Hu
authors.forename: Wei
authors.initials: W
authors.lastname: Cui
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000069059:Atorvastatin / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D053453:Caspase 9 / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D005786:Gene Expression Regulation; D000071679:Glycogen Synthase Kinase 3 beta / Q000235:genetics* / Q000378:metabolism; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D015428:Myocardial Reperfusion Injury / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D061251:Primary Cell Culture; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
chemical_list: D002316:Cardiotonic Agents; C552425:MIRN199 microRNA, rat; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D000069059:Atorvastatin; D000071679:Glycogen Synthase Kinase 3 beta; C506435:Casp9 protein, rat; D053453:Caspase 9